Radiopharm Theranostics Ltd ADR (RADX)

$16.19 +10.59 (189.11%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 10,245
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; a...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9824 5254
Fax: 61 3 9822 7735
Address:
62 Lygon Street, Level 3, Carlton, Australia
PolloStock
PolloStock Oct. 4 at 10:22 PM
Love $RADX long term, but not the same as $CATX. CATX has way more cash on hand.
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 4 at 1:10 PM
Bristol Myers Squibb will pay $350M-plus to add prostate cancer imaging agent $RADX https://radiologybusiness.com/topics/healthcare-management/mergers-and-acquisitions/bristol-myers-squibb-will-pay-350m-plus-add-prostate-cancer-imaging-agent
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 4 at 12:02 PM
Lantheus set to close $750M acquisition of PET agent developer Life Molecular Imaging $RADX $LNTH https://radiologybusiness.com/topics/healthcare-management/mergers-and-acquisitions/lantheus-set-close-750m-acquisition-pet-agent-developer-life-molecular-imaging
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 4 at 11:45 AM
$RADX Do your due diligence https://scr.zacks.com/news/news-details/2025/RADX-RAD101-Imaging-Recurring-Brain-Metastases-article/default.aspx $PYXS $IMNM $ADCT $INMB
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 4 at 12:43 AM
$RADX $CATX $LNTH
0 · Reply
biospeculator
biospeculator Oct. 3 at 11:10 PM
$RADX A huge shoutout and thank you for all the great information regarding RADX and the industry to Radioisotope25 and IanMaui and RADX_enjoyer and several others. Please keep posting relevant information so each of us can own our own trades. I am LONG. GLTA
1 · Reply
RadioIsotope25
RadioIsotope25 Oct. 3 at 11:00 PM
Sanofi – NANOBODY® technology - YouTube $RADX https://www.youtube.com/watch?v=pPwZprbOVro
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 3 at 10:35 PM
Everything I am reading says nanobodies not peptides are optimal for her2 and pdl-1 cancer targeting. Good news for $RADX
2 · Reply
packer123
packer123 Oct. 3 at 4:41 PM
$RADX Man Small caps are breaking out. One good reading. This will take to 30’s Come on.
2 · Reply
RadioIsotope25
RadioIsotope25 Oct. 3 at 3:48 PM
$RADX vs $CATX
2 · Reply
Latest News on RADX
No data available.
PolloStock
PolloStock Oct. 4 at 10:22 PM
Love $RADX long term, but not the same as $CATX. CATX has way more cash on hand.
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 4 at 1:10 PM
Bristol Myers Squibb will pay $350M-plus to add prostate cancer imaging agent $RADX https://radiologybusiness.com/topics/healthcare-management/mergers-and-acquisitions/bristol-myers-squibb-will-pay-350m-plus-add-prostate-cancer-imaging-agent
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 4 at 12:02 PM
Lantheus set to close $750M acquisition of PET agent developer Life Molecular Imaging $RADX $LNTH https://radiologybusiness.com/topics/healthcare-management/mergers-and-acquisitions/lantheus-set-close-750m-acquisition-pet-agent-developer-life-molecular-imaging
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 4 at 11:45 AM
$RADX Do your due diligence https://scr.zacks.com/news/news-details/2025/RADX-RAD101-Imaging-Recurring-Brain-Metastases-article/default.aspx $PYXS $IMNM $ADCT $INMB
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 4 at 12:43 AM
$RADX $CATX $LNTH
0 · Reply
biospeculator
biospeculator Oct. 3 at 11:10 PM
$RADX A huge shoutout and thank you for all the great information regarding RADX and the industry to Radioisotope25 and IanMaui and RADX_enjoyer and several others. Please keep posting relevant information so each of us can own our own trades. I am LONG. GLTA
1 · Reply
RadioIsotope25
RadioIsotope25 Oct. 3 at 11:00 PM
Sanofi – NANOBODY® technology - YouTube $RADX https://www.youtube.com/watch?v=pPwZprbOVro
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 3 at 10:35 PM
Everything I am reading says nanobodies not peptides are optimal for her2 and pdl-1 cancer targeting. Good news for $RADX
2 · Reply
packer123
packer123 Oct. 3 at 4:41 PM
$RADX Man Small caps are breaking out. One good reading. This will take to 30’s Come on.
2 · Reply
RadioIsotope25
RadioIsotope25 Oct. 3 at 3:48 PM
$RADX vs $CATX
2 · Reply
BillionerOfKing
BillionerOfKing Oct. 3 at 2:43 PM
$RADX Current Stock Price: $6.00 No options data available.
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 3 at 2:02 PM
$RADX Race Oncology is trading at $700 million aud market cap with 1/6th of the pipeline in Australia 🇦🇺… Ticker: RAC
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 3 at 1:39 PM
$RADX Closed at $6.60 equivalent in Australia last night.
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 3 at 10:17 AM
$RADX that spread is crazy.
0 · Reply
biospeculator
biospeculator Oct. 2 at 5:15 PM
$RADX Ok, some on the board say let's compare apples to apples or in our case CATX vs RADX. Both have solid pipelines and major partnerships. But, CATX made a market cap run on previous good news to 1B+. Now it's pullback at 250M, due to compression in the space with LNTH and TLX both down 50%+. So, IF RADX has similar good news on the coming trial results then the market cap COULD run to 500M also as an overshoot similar to CATX. That is $50-$60 a share. Not pumping just the facts. GLTA
4 · Reply
Orlandotrader
Orlandotrader Oct. 2 at 3:03 PM
$RADX Pumpers please Disappear and let this play out. I post Technicals and Reiterate what’s the company has issued. Just the Facts.
1 · Reply
outlawinvestor1
outlawinvestor1 Oct. 2 at 2:37 PM
$RADX $MNPR and $RADX are completely different companies with different value drivers. one is not an indicator of what the other can do. they're both good opportunities imho, but no need to compare.
3 · Reply
IanMaui
IanMaui Oct. 2 at 2:08 PM
$RADX I am calling it on MNPR. What a run, 2200%. 2X my mkt cap goal of $300M. I will be adding to my position in RADX. This is also a $250M+ company, easily. Nor will I be selling the position when it begins rise. The small float will dictate a similar accumulation as MNPR as RADX begins to find institutional investors, small cap funds, hedgies.
2 · Reply
RadioIsotope25
RadioIsotope25 Oct. 2 at 2:03 PM
$RADX Stop pumping i need to cover my short
2 · Reply
Lalalilala
Lalalilala Oct. 2 at 1:53 PM
$RADX I just asked for 800 shares at 5.90, we'll see if it goes through.....
1 · Reply
Orlandotrader
Orlandotrader Oct. 2 at 12:45 PM
$RADX Seems All Clinical Trials are Progressing Nicely.
1 · Reply
Orlandotrader
Orlandotrader Oct. 2 at 12:30 PM
$RADX Radiopharm receives DSMC recommendation to advance Phase 1 ‘HEAT’ trial Radiopharm (RADX) Theranostics announced that it has received a positive recommendation from the Data Safety and Monitoring Committee to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202, to the next dose level of 75mCi in the Phase 1 ‘HEAT’ clinical trial The DSMC reviewed the first cohort of patients treated with 30mCi of Lu177-RAD202 and confirmed there was positive safety, pharmacokinetic, and biodistribution data and agreed that the study may continue without modifications and accelerate to the second cohort of patients at 75mCi of Lu177-RAD202.
0 · Reply